geneonyxdec202011:start
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
| geneonyxdec202011:start [2015/05/06 18:10] – magiero | geneonyxdec202011:start [2015/05/06 18:46] (current) – magiero | ||
|---|---|---|---|
| Line 26: | Line 26: | ||
| • The genetic era now opens up the possibility to utilise a deeper understanding of genetics in a customised, i.e. person-specific, | • The genetic era now opens up the possibility to utilise a deeper understanding of genetics in a customised, i.e. person-specific, | ||
| • A single-nucleotide polymorphism (SNP) found in the target //(i.e. molecule to be affected)// of an active ingredient //(i.e. the key molecule in the drug)// provides information on the quality of the expected response\\ | • A single-nucleotide polymorphism (SNP) found in the target //(i.e. molecule to be affected)// of an active ingredient //(i.e. the key molecule in the drug)// provides information on the quality of the expected response\\ | ||
| - | • //Use cross-validation | + | • //Use __CROSS-VALIDATION__ |
| • This method uses detection of SNP to estimate protein-protein interaction between an ingredient and its direct or indirect target.\\ | • This method uses detection of SNP to estimate protein-protein interaction between an ingredient and its direct or indirect target.\\ | ||
| • **As previously discussed**, | • **As previously discussed**, | ||
| Line 49: | Line 49: | ||
| • 5 questions are asked (1: SNP has poor effect on ingredient to 5: SNP has considerable effect on ingredient) to determine SIF.\\ | • 5 questions are asked (1: SNP has poor effect on ingredient to 5: SNP has considerable effect on ingredient) to determine SIF.\\ | ||
| • A " | • A " | ||
| + | |||
| + | ^ ^ | ||
| + | ^ ^ | ||
| + | ^ Ingredient ^ Target | ||
| + | | Niacin | ||
| + | | Collagen | ||
| + | |||
| + | |||
| • SNPs are organized into level of interaction with metabolism pathway.\\ | • SNPs are organized into level of interaction with metabolism pathway.\\ | ||
| * 1st level: First protein to interact with ingredient (receptor or enzyme responsible for chemical interaction or ingredient modification). | * 1st level: First protein to interact with ingredient (receptor or enzyme responsible for chemical interaction or ingredient modification). | ||
| Line 59: | Line 67: | ||
| === - 3: Design of specific primers to amplify the specific SNP associated to ingredients === | === - 3: Design of specific primers to amplify the specific SNP associated to ingredients === | ||
| + | • One of the key aspects of this method is to design specific primers to target the right genotype.\\ | ||
| + | • To amplify DNA, several standard methods can be used such as polymerase chain reaction (PCR), SNAP, or LAPM assay.\\ | ||
| + | • All these techniques are based on the selection of accurate primers.\\ | ||
| + | • Primers were selected according to a number of criteria, including: primer length, the terminal nucleotide in the primer, reasonable GC content and Tm.\\ | ||
| === - 4: Matching ingredients to their target and the associated SNP === | === - 4: Matching ingredients to their target and the associated SNP === | ||
| + | |||
| + | • Each ingredient has the ability to be “metabolised” by a person. This ability is based upon the genetic makeup of this person. \\ | ||
| + | • **The metabolic pathways of many ingredients are identified and a list is created which details those ingredients that either become inactive due to the presence of a SNP, or a highly beneficial ingredient because the SNP creates a failing or fault that is corrected by this ingredient.**\\ | ||
| + | • __Once the ingredients have been matched to their target and the associated SNP__, this information can be entered into a table or database for future reference.\\ | ||
| === - 5: Correlation between ingredients and efficacy associated to SNP === | === - 5: Correlation between ingredients and efficacy associated to SNP === | ||
| + | |||
| + | • It can now be determined if an ingredient is efficient or not when affected by a specific SNP(s) in its target (the aforementioned __CROSS-VALIDATION__? | ||
| + | • The final decision reflects the previously determined efficacy of the ingredient.\\ | ||
| + | • If the target is not functional the ingredient will not be recommended. (i.e. customer' | ||
| + | • In contrast, if the target is not affected by the SNP the ingredient will be recommended (i.e. just a " | ||
| + | • If the SNP provides again enhanced efficacy of an ingredient, the dosage of this ingredient might be considered before being recommended\\ | ||
| + | • taken into consideration is the genotype identified by the test. This will affect the correlation given on the efficacy of the test\\ | ||
| === - 6: Application: | === - 6: Application: | ||
geneonyxdec202011/start.1430935846.txt.gz · Last modified: 2015/05/06 18:10 by magiero